Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

NCT07006688 is registered in ClinicalTrials.gov with Servier Bio-Innovation LLC as lead sponsor.

NCT NCT07006688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07006688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
Lead sponsor
Servier Bio-Innovation LLC
Phase
Phase 1
Overall status
Recruiting
Start date
January 14, 2026
Completion date
August 31, 2028
Enrollment
30 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

idh1-mutated malignancies